SOPH — SOPHiA GENETICS S.A. stock price, charts and financials

NASDAQ·Healthcare·Medical - Healthcare Information Services·Switzerland

Latest market price

7.67

-0.04-0.52%

Overview Short InterestFilings

SOPHQT80SOPHiA GENETICS S.A.·NASDAQ

Overview Short InterestFilings

7.67-0.52%

Loading chart...

Signal & projected range

Insider selling clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CTEV+7.00%$34.87 NRC+0.56%$20.45 EVH+4.43%$4.13 TBRG+0.00%$26.24 PHR-1.08%$12.38 HSTM+2.44%$29.42 GDRX+3.55%$3.81 CERT-2.18%$8.02

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.18	Insider Own	11.84%	Shs Outstand	69.71M	Perf Week	35.98%

Market Cap	537.50M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	-7.13%	Shs Float	59.83M	Perf Month	32.47%

Enterprise Value	534.53M	PEG	0.40	EPS next Q	-	Inst Own	-	Short Float	1.11%	Perf Quarter	42.78%

Income	-79.33M	P/S	6.62	EPS this Y	20.51%	Inst Trans	-	Short Ratio	3.31	Perf Half Y	67.61%

Sales	81.18M	P/B	12.00	EPS next Y	33.26%	ROA	-51.55%	Short Interest	661.35K	Perf YTD	65.10%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-140.63%	52W High	7.82 -1.91%	Perf Year	144.76%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-63.43%	52W Low	2.94 160.47%	Perf 3Y	105.05%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	17.06% 22.42%	Gross Margin	67.28%	Volatility	12.72% 7.65%	Perf 5Y	-50.73%

Dividend TTM	-	EV/Sales	6.58	EPS Y/Y TTM	-24.21%	Oper. Margin	-88.39%	ATR (14)	0.53	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.90	Sales Y/Y TTM	24.62%	Profit Margin	-99.70%	RSI (14)	71.62	Recom	2.13

Dividend Gr. 3/5Y	-	Current Ratio	2.06	EPS Q/Q	-3.85%	SMA20	27.12%	Beta	0.95	Target Price	11.50

Payout	0.00%	Debt/Eq	1.37	Sales Q/Q	22.22%	SMA50	37.34%	Rel Volume	3.25	Prev Close	7.71

Employees	415	LT Debt/Eq	1.30	Earnings	Nov 03	SMA200	54.04%	Avg Volume	296.76K	Price	7.67

IPO Date	Jul 23, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.13% 6.29%	Net Debt/EBITDA	0.04	Volume	963,487	Change	-0.52%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-05-26	Reiterated	HC Wainwright & Co.	Buy	$12 → $14
Aug-05-26	Reiterated	BTIG	Buy	$8.00 → $9.00
Jul-20-26	Initiated	H.C	Buy	$12
Apr-15-26	Reiterated	BTIG	Buy	$7.00 → $8.00
Mar-03-26	Reiterated	BTIG	Buy	$5.00 → $7.00
Jan-26-26	Reiterated	Guggenheim	Buy	$6.00 → $7.00
Mar-06-25	Reiterated	BTIG	Buy	$6.00 → $5.00
Aug-07-24	Reiterated	Morgan Stanley	Overweight	$5.00
Jun-27-24	Reiterated	Guggenheim		$6.00
Jan-03-23	Reiterated	BTIG	Buy	$6.00

Latest News

Aug-05-26

Aug-05-2611:39AM

SOPHiA GENETICS SA 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha

Aug-04-26

Aug-04-2605:10PM

SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcriptseekingalpha.com

02:06PM

SOPHiA GENETICS Q2 Earnings Call Highlightsmarketbeat.com

06:45AM

SOPHiA GENETICS Reports Second Quarter 2026 Resultsprnewswire.com

06:15AM

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapiesprnewswire.com

Jul-21-26

Jul-21-2608:00AM

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026prnewswire.com

Jul-20-26

Jul-20-2608:39AM

This Charles Schwab Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For MondayBenzinga

Jun-18-26

Jun-18-2608:22AM

SOPHiA Genetics: Strong Growth Meets A Critical Execution PhaseSeekingAlpha

Jun-17-26

Jun-17-2608:44AM

Stock Market Today: Dow Futures Tumble, S&P 500, Nasdaq Gains As Investors Await FOMC Decision— Amkor, La-Z-Boy In Focus (UPDATED)Benzinga

08:03AM

Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga

02:50AM

CarMax, Jabil And 3 Stocks To Watch Heading Into WednesdayBenzinga

Jun-16-26

Jun-16-2604:22PM

SOPHiA GENETICS Commences Ordinary Shares Offering; Terms UndisclosedBenzinga

Jun-15-26

Jun-15-2608:09AM

BTIG Reiterates Buy on Sophia Genetics, Maintains $8 Price TargetBenzinga

Company

SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	81	77	65	—	—	—	—	—
Cost of Goods Sold Incl. D&A	27	29	21	—	—	—	—	—
Gross Profit	55	48	44	—	—	—	—	—
Selling, General and Administrative Excl. Other	92	85	76	—	—	—	—	—
Research and Development	37	34	34	—	—	—	—	—
Other Operating Expense	-2	0	1	—	—	—	—	—
Operating Income	-72	-71	-67	—	—	—	—	—
Interest Expense	7	5	2	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-3	-3	7	—	—	—	—	—
Net Income Before Taxes	-80	-78	-61	—	—	—	—	—
Income Taxes	2	1	1	—	—	—	—	—
Consolidated Net Income	-80	-79	-62	—	—	—	—	—
Net Income From Continuing Operations	-80	-79	-62	—	—	—	—	—
Net Income	-80	-79	-62	—	—	—	—	—
EPS (Recurring)	-1.18	-1.17	-0.95	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.18	-1.17	-0.95	—	—	—	—	—
EPS (Diluted)	-1.18	-1.17	-0.95	—	—	—	—	—
EBITDA	-66	-64	-51	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	6.72	4.12	3.12	—	—	—	—	—
Gross Margin	67.90	62.34	67.69	—	—	—	—	—
Operating Margin	-88.89	-92.21	-103.08	—	—	—	—	—
Net Margin	-98.77	-102.60	-95.38	—	—	—	—	—
Shares Outstanding	71	68	66	—	—	—	—	—
Market Capitalization	545	318	203	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xu Zhenyu	Chief Scientific Officer	Aug 07 '26	Option Exercise	3.28	7,000	22,960	607,887	Aug 07
Xu Zhenyu	Chief Scientific Officer	Aug 07 '26	Sale	7.29	17,000	123,911	590,887	Aug 07
Xu Zhenyu	Chief Scientific Officer	Aug 05 '26	Option Exercise	3.28	3,000	9,840	603,887	Aug 07
Xu Zhenyu	Chief Scientific Officer	Aug 05 '26	Sale	7.00	3,000	21,013	600,887	Aug 07
Verma Abhimanyu	Chief Technology Officer	Aug 04 '26	Sale	6.95	5,000	34,772	187,171	Aug 05
Camblong Jurgi	Executive Chairman	Aug 04 '26	Sale	6.92	20,000	138,412	3,472,822	Aug 05
Xu Zhenyu	Chief Scientific Officer	Aug 04 '26	Sale	6.92	10,000	69,168	600,887	Aug 05
Menu Philippe	Chief Medical Officer	Jul 27 '26	Sale	5.66	5,000	28,306	223,387	Jul 28
Camblong Jurgi	Executive Chairman	Jul 21 '26	Sale	6.63	20,000	132,654	3,492,822	Jul 22
Camblong Jurgi	Executive Chairman	Jul 20 '26	Option Exercise	3.16	4,581	14,476	3,517,403	Jul 22
Camblong Jurgi	Executive Chairman	Jul 20 '26	Sale	6.29	24,381	153,445	3,512,822	Jul 22
Menu Philippe	Chief Medical Officer	Jul 13 '26	Sale	5.70	5,000	28,505	228,387	Jul 14
Xu Zhenyu	Chief Scientific Officer	Jul 13 '26	Sale	5.70	4,000	22,819	610,887	Jul 14
Camblong Jurgi	Executive Chairman	Jul 10 '26	Sale	5.62	8,500	47,791	3,532,622	Jul 14
Camblong Jurgi	Executive Chairman	Jul 07 '26	Sale	5.28	17,685	93,327	3,541,122	Jul 08

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.